TY - JOUR
T1 - Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
AU - Parry, Erin M.
AU - Leshchiner, Ignaty
AU - Guièze, Romain
AU - Johnson, Connor
AU - Tausch, Eugen
AU - Parikh, Sameer A.
AU - Lemvigh, Camilla
AU - Broséus, Julien
AU - Hergalant, Sébastien
AU - Messer, Conor
AU - Utro, Filippo
AU - Levovitz, Chaya
AU - Rhrissorrakrai, Kahn
AU - Li, Liang
AU - Rosebrock, Daniel
AU - Yin, Shanye
AU - Deng, Stephanie
AU - Slowik, Kara
AU - Jacobs, Raquel
AU - Huang, Teddy
AU - Li, Shuqiang
AU - Fell, Geoff
AU - Redd, Robert
AU - Lin, Ziao
AU - Knisbacher, Binyamin A.
AU - Livitz, Dimitri
AU - Schneider, Christof
AU - Ruthen, Neil
AU - Elagina, Liudmila
AU - Taylor-Weiner, Amaro
AU - Persaud, Bria
AU - Martinez, Aina
AU - Fernandes, Stacey M.
AU - Purroy, Noelia
AU - Anandappa, Annabelle J.
AU - Ma, Jialin
AU - Hess, Julian
AU - Rassenti, Laura Z.
AU - Kipps, Thomas J.
AU - Jain, Nitin
AU - Wierda, William
AU - Cymbalista, Florence
AU - Feugier, Pierre
AU - Kay, Neil E.
AU - Livak, Kenneth J.
AU - Danysh, Brian P.
AU - Stewart, Chip
AU - Neuberg, Donna
AU - Davids, Matthew S.
AU - Brown, Jennifer R.
AU - Parida, Laxmi
AU - Stilgenbauer, Stephan
AU - Getz, Gad
AU - Wu, Catherine J.
N1 - Funding Information:
We thank C. Hahn, E. Ten Hacken, W. Zhang, S. Gohil and L. Werner for helpful discussions. We thank C. Patterson, S. Pollock, O. Olive, C. J. Shaughnessy, F. Dao and H. Lyon for assistance in data collection and organization and S. Belkin and C. Birger for assistance in data storage. We thank T. Lehmberg, M. McDonough, C. Galler and M. Collins for assistance in sample collection and biobanking. We thank the patients, their families and the investigators of the clinical trials for providing samples and clinical data. This study was supported by NIH/NCI P01 CA206978 (to C.J.W. and G.G.) and NCI (1U10CA180861-01) (to C.J.W.). The work is partially supported by the Broad/IBM Cancer Resistance Research Project (I.L., G.G. and L.P.) and a grant from Force Hemato (R.G.). Individual support was provided by DDCF Physician-Scientist Fellowship (E.M.P.), Dana-Farber Flames FLAIR fellowship (E.M.P.), ASCO Conquer Cancer Young Investigator Award (E.M.P.), Fishman Family Fund (R.G. and C.L.), EMBO fellowship ALTF 14-2018 (B.A.K.), NCI Research Specialist Award R50CA251956 (S.L.) and NIH/NCI R21CA267527-01 (S.Y.). Additional research support was provided by NIH R01 CA213442 (J.R.B.), Melton Family Foundation (J.R.B.), NIH/NCI R01-CA236361 (T.J.K.) and the Deutsche Forschungsgemeinschaft (DFG) SFB1074 subprojects B10 (E.T.) and subprojects B1 and B2 (E.T., C.S. and S.S.)
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2023/1
Y1 - 2023/1
N2 - Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics underlying this transformation, we computationally deconvoluted admixtures of CLL and RS cells from 52 patients with RS, evaluating paired CLL–RS whole-exome sequencing data. We discovered RS-specific somatic driver mutations (including IRF2BP2, SRSF1, B2M, DNMT3A and CCND3), recurrent copy-number alterations beyond del(9p21)(CDKN2A/B), whole-genome duplication and chromothripsis, which were confirmed in 45 independent RS cases and in an external set of RS whole genomes. Through unsupervised clustering, clonally related RS was largely distinct from diffuse large B cell lymphoma. We distinguished pathways that were dysregulated in RS versus CLL, and detected clonal evolution of transformation at single-cell resolution, identifying intermediate cell states. Our study defines distinct molecular subtypes of RS and highlights cell-free DNA analysis as a potential tool for early diagnosis and monitoring.
AB - Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics underlying this transformation, we computationally deconvoluted admixtures of CLL and RS cells from 52 patients with RS, evaluating paired CLL–RS whole-exome sequencing data. We discovered RS-specific somatic driver mutations (including IRF2BP2, SRSF1, B2M, DNMT3A and CCND3), recurrent copy-number alterations beyond del(9p21)(CDKN2A/B), whole-genome duplication and chromothripsis, which were confirmed in 45 independent RS cases and in an external set of RS whole genomes. Through unsupervised clustering, clonally related RS was largely distinct from diffuse large B cell lymphoma. We distinguished pathways that were dysregulated in RS versus CLL, and detected clonal evolution of transformation at single-cell resolution, identifying intermediate cell states. Our study defines distinct molecular subtypes of RS and highlights cell-free DNA analysis as a potential tool for early diagnosis and monitoring.
UR - http://www.scopus.com/inward/record.url?scp=85145920664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145920664&partnerID=8YFLogxK
U2 - 10.1038/s41591-022-02113-6
DO - 10.1038/s41591-022-02113-6
M3 - Article
C2 - 36624313
AN - SCOPUS:85145920664
SN - 1078-8956
VL - 29
SP - 158
EP - 169
JO - Nature Medicine
JF - Nature Medicine
IS - 1
ER -